Figure 3. The combination of trastuzumab with NAC supplementation results in slower tumor growth.

The effect of the different treatment on JIMT1 (HER2+/MUC4+) and SKBr3 (HER2+/MUC4) tumors in dual-tumor-bearing mice randomized to the four treatment arms CS (Control+Saline; blue, n = 10), CT (Control+Trastuzumab; purple, n = 10), NS (NAC+Saline; green, n = 9) and NT (NAC+Trastuzumab; red n = 10) is represented per methodologies as follows: Tumor growth of JIMT1 (A) and SKBr3 (B) tumors monitored through caliper measurements. Data are represented as mean ± SEM, expressed in cm³ for tumor volume, with ***p < 0.001.